Post Content
Autolus Therapeutics plc (NASDAQ:AUTL) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Autolus Therapeutics plc (NASDAQ:AUTL) is a consensus buy among all eleven analysts covering the stock. With a median price target of $10, the stock boasts an upside potential of 495.24%. Among the analysts positive on the stock is Yanan Zhu, an analyst at Wells Fargo, who reaffirmed a ‘Buy’ rating on the company, setting a price target of $5 on December 8. This translates to an upside potential of around 198%.
On the same day, Autolus Therapeutics plc (NASDAQ:AUTL) delivered preliminary data from its Phase 1 CARLYSLE trial, which demonstrated positive responses in patients suffering from refractory systemic lupus erythematosus (srSLE) targeted by CAR-T cell therapy obecabtagene autoleucel (obe-cel).
During the presentation at the American Society of Hematology Annual Meeting, the study’s data showed that while three patients achieved complete response, five patients achieved DORIS response criteria and exhibited a median onset of 5.1 months. Nine patients were assessable for safety across both the 50 million and 100 million cell dose cohorts.
As stated by Dr. Matthias Will, the Chief Development Officer,
“Data reported from the CARLYSLE trial show an encouraging high rate of DORIS responses and a deep reset in the B cell compartment induced by obe-cel.”
Autolus Therapeutics plc (NASDAQ:AUTL) is a U.K.-based clinical-stage biopharmaceutical company engaging in solutions for cancer and autoimmune diseases. Incorporated in 2014, the company is dedicated to creating “next-generation T-cell immunotherapies for cancer and autoimmune diseases.”
While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.